[et_pb_section fb_built=”1″ admin_label=”News T-Hero Section” module_class=”hero tert” _builder_version=”4.18.0″ _module_preset=”default” background_image=”https:\/\/aafa.org\/wp-content\/uploads\/2022\/07\/AAFA-Website_Tertiary_News.jpg” background_position=”top_right” custom_padding=”1%||1%||true|false” global_module=”2297″ saved_tabs=”all” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.17.4″ _module_preset=”default” background_enable_image=”off” background_size=”initial” background_position=”bottom_left” background_horizontal_offset=”0%” custom_margin=”||||false|false” custom_padding=”2%||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Nav Parent Title” module_class=”tert-parent” _builder_version=”4.20.4″ _module_preset=”default” header_2_font=”|600|||||||” header_2_text_align=”left” header_2_text_color=”#FFFFFF” header_2_font_size=”32px” custom_margin=”||0px||false|false” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_code admin_label=”Breadcrumbs” module_class=”bcrumb” _builder_version=”4.17.4″ _module_preset=”default” text_orientation=”left” custom_margin=”||||false|false” custom_padding=”||||false|false” custom_css_main_element=”font-size:16px;||color: #fff;” global_colors_info=”{}”][\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Main Content” _builder_version=”4.17.4″ _module_preset=”default” background_enable_image=”off” background_size=”initial” background_position=”bottom_right” custom_padding=”2%||2%||true|false” collapsed=”off” global_colors_info=”{}”][et_pb_row admin_label=”Title Row” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_title author=”off” comments=”off” featured_image=”off” admin_label=”Blog Post Title” _builder_version=”4.18.0″ _module_preset=”default” title_level=”h2″ title_font=”|600|||||||” title_text_color=”#008C99″ title_font_size=”39px” meta_font=”|700|||||||” meta_text_color=”#505050″ meta_font_size=”20px” title_font_size_tablet=”30px” title_font_size_phone=”26px” title_font_size_last_edited=”on|phone” meta_font_size_tablet=”20px” meta_font_size_phone=”16px” meta_font_size_last_edited=”on|phone” global_colors_info=”{}”][\/et_pb_post_title][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=”Content Row” module_class=”blog-single” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Page Content” module_class=”secondary-intro” _builder_version=”4.24.2″ _module_preset=”default” text_text_color=”#505050″ text_line_height=”1.5em” header_2_font=”|600|||||||” header_2_text_color=”#008c99″ header_2_font_size=”39px” custom_margin=”||3%||false|false” global_colors_info=”{}”]<\/p>\n
Patient advocacy group continues push to reduce costs, improve access <\/em><\/p>\n Washington, D.C., March 18, 2024 \u2013 The Asthma and Allergy Foundation of America (AAFA) welcomes efforts to make asthma medicines more affordable and accessible. AAFA continues to lead advocacy efforts to change the drug pricing ecosystem on behalf of the 27 million people in the United States with asthma.<\/p>\n AstraZeneca announced<\/a> it will cap out-of-pocket costs for its entire U.S. inhaled respiratory portfolio at $35 per month for patients who have commercial insurance or no insurance.<\/p>\n “AAFA applauds AstraZeneca\u2019s announcement to cap costs of asthma inhalers and urges other manufacturers to take similar steps to make medications more affordable and accessible,\u201d said AAFA President and CEO Kenneth Mendez. \u201cAAFA continues to raise the voice of the patient community and draw attention to the ways America\u2019s complex drug pricing ecosystem makes asthma medications more expensive<\/a> for people who need them most. Drug manufacturers, pharmacy benefit managers, insurers, employers, and the government operate in a perverse system that drives prices higher\u2014and all stakeholders must work together to improve affordability and access.\u201d<\/p>\n Access to affordable drugs is a critical component of reducing racial disparities in asthma. Black and Hispanic individuals not only experience higher rates of asthma but also are more likely to be uninsured or underinsured. Deaths due to asthma\u2014although decreasing overall\u2014occur at a much higher rate in the Black and Puerto Rican populations than in the White population. Black individuals are nearly three times as likely to die from asthma than White individuals.<\/p>\n Last fall, AAFA shared patient stories and its Asthma Disparities in America report<\/a> with the Senate Health, Education, Labor, and Pensions (HELP) Committee which then launched an investigation into the high price of asthma inhalers<\/a> early this year.<\/p>\n AAFA\u2019s\u00a0research indicates that when the cost of medicine becomes a barrier to treatment<\/a>, people with asthma\u00a0resort to rationing or simply discontinue use.<\/a><\/p>\n Access to asthma medications can save lives, reduce hospitalizations, and lower the more than $82 billion in annual costs to the U.S. economy from this chronic disease. But the U.S. health care system is complex, and often leaves patients with few affordable options.<\/p>\n <\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=”Content Row” module_class=”blog-single” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Press Contact” _builder_version=”4.24.2″ _module_preset=”default” text_text_color=”#505050″ link_font=”||||on|||#008c99|” link_text_color=”#008c99″ header_2_font=”|600|||||||” header_2_text_color=”#008c99″ header_2_font_size=”39px” header_3_font=”|600|||||||” header_3_text_align=”left” header_3_text_color=”#008c99″ header_3_font_size=”28px” global_colors_info=”{}”]<\/p>\n Press Contact:<\/strong> [\/et_pb_text][et_pb_text admin_label=”About ” _builder_version=”4.24.2″ _module_preset=”default” text_text_color=”#505050″ link_font=”||||on|||#008c99|” link_text_color=”#008c99″ link_line_height=”1.7em” ul_line_height=”1.7em” header_2_font=”|600|||||||” header_2_text_color=”#008c99″ header_2_font_size=”39px” header_3_font=”|600|||||||” header_3_text_align=”left” header_3_text_color=”#008c99″ header_3_font_size=”28px” background_color=”#F5EDDF” custom_padding=”4%|4%|4%|4%|true|true” box_shadow_style=”preset2″ global_colors_info=”{}”]<\/p>\n
\n
Andy Spears
Asthma and Allergy Foundation of America (AAFA)
media@aafa.org<\/p>\n